Abstract: Predictive models are built for the estimation of adverse health likelihood by identifying candidate model risk variables, constructing a model form for an outcome likelihood model that estimates the likelihood of an adverse outcome type using a group of risk variables selected from the set of candidate model risk variables and by classifying each selected risk variable into either a baseline group or a dynamic group. Additionally, predictive models are built by constructing separate baseline and dynamic outcome likelihood model forms and by fitting the constructed model forms to a training data set to produce final models to be used as scoring functions that compute a baseline outcome likelihood and a dynamic outcome likelihood for patient data that is not represented in the training data set. The predictive models can be used with alerting and attribution algorithms to predict the likelihood of an adverse outcome for individuals receiving care.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: Verified electronic products are created and distributed by an electronic platform, which includes a client interface, a creator interface, a decider interface, and a backer interface. An unverified product associated with a creator entity is received through the creator interface, where the unverified product comprises an electronic product having a set of clauses. A decider entity and backer entity are associated with the unverified product, which is converted to a verified product. The verified product is then added to a search engine associated with other previously verified products to define a collection of searchable verified products. Client information is obtained through the client interface and is used to identify a verified product from the collection of searchable verified products via the search engine. Based on the identified verified product, and instrument is built and is communicated to the client entity via the client interface for acceptance by the client entity.

Abstract: Predictive models are built for the estimation of adverse health likelihood by identifying candidate model risk variables, constructing a model form for an outcome likelihood model that estimates the likelihood of an adverse outcome type using a group of risk variables selected from the set of candidate model risk variables and by classifying each selected risk variable into either a baseline group or a dynamic group. Additionally, predictive models are built by constructing separate baseline and dynamic outcome likelihood model forms and by fitting the constructed model forms to a training data set to produce final models to be used as scoring functions that compute a baseline outcome likelihood and a dynamic outcome likelihood for patient data that is not represented in the training data set. The predictive models can be used with alerting and attribution algorithms to predict the likelihood of an adverse outcome for individuals receiving care.

Abstract: A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.

Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Abstract: A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.

Abstract: Verified electronic products are created and distributed by an electronic platform, which includes a client interface, a creator interface, a decider interface, and a backer interface. An unverified product associated with a creator entity is received through the creator interface, where the unverified product comprises an electronic product having a set of clauses. A decider entity and backer entity are associated with the unverified product, which is converted to a verified product. The verified product is then added to a search engine associated with other previously verified products to define a collection of searchable verified products. Client information is obtained through the client interface and is used to identify a verified product from the collection of searchable verified products via the search engine. Based on the identified verified product, and instrument is built and is communicated to the client entity via the client interface for acceptance by the client entity.

Abstract: A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.

Abstract: A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.

Abstract: Predictive models are built for the estimation of adverse health likelihood by identifying candidate model risk variables, constructing a model form for an outcome likelihood model that estimates the likelihood of an adverse outcome type using a group of risk variables selected from the set of candidate model risk variables and by classifying each selected risk variable into either a baseline group or a dynamic group. Additionally, predictive models are built by constructing separate baseline and dynamic outcome likelihood model forms and by fitting the constructed model forms to a training data set to produce final models to be used as scoring functions that compute a baseline outcome likelihood and a dynamic outcome likelihood for patient data that is not represented in the training data set. The predictive models can be used with alerting and attribution algorithms to predict the likelihood of an adverse outcome for individuals receiving care.

Abstract: An apparatus for dermatological treatments has a base equipment 10 to which differing application heads 14 can be connected, selectively via flexible conduits 12, for the purpose of applying radiation, in particular of an LED and of a laser or of a high-energy flashbulb.

Abstract: A medical and/or cosmetic radiation device has a plurality of LEDs (24a, 24b) which emit at different wavelengths.

Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Abstract: A biodegradable radioactive seed placement system is provided comprising a thin, flexible, biodegradable sheath having at least one radioactive isotope seed positioned between a first end and a second end. Additionally, at least one spacer can be positioned between the first end and the second end adjacent to a radioactive isotope seed. The sheath/seed assembly can be loaded into a needle and implanted from the needle into a patient.

Abstract: The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Abstract: The present invention provides a novel method to determine the likelihood of effectiveness of a treatment in an individual affected with or at risk for developing cancer. The method involves detecting the presence or absence of Met amplification in an individual. The presence of Met amplification indicates that a Met targeting treatment is likely to be effective. Preferably, the Met targeting treatment is PHA-665752 or PF-02341066. In addition, the present methods allow for the detection of cancer in an individual, wherein the presence of Met amplification indicates that cancer is present and further that it will be treatable, namely with a Met targeting treatment.

Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.